Upstream Bio, Inc.
UPB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.12 | 0.00 | -2.24 |
| FCF Yield | -6.65% | -12.54% | -2.35% | -1.26% |
| EV / EBITDA | -12.34 | -8.09 | -19.80 | -58.19 |
| Quality | ||||
| ROIC | -10.79% | -7.15% | -5.57% | -8.47% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.66 | 0.98 | 1.51 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 65.18% | 1,396,319.42% | 1,319,140.46% | 1,333,163.89% |
| Free Cash Flow Growth | 4.56% | -107.94% | -38.56% | -77.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 2.18 | 12.34 | 1.64 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,773.94 | -9,598.52 | -7,249.00 | -31,331.66 |